Alemtuzumab and Multiple Sclerosis: Another Note of Caution

JAMA Neurol. 2016 Jun 1;73(6):637-8. doi: 10.1001/jamaneurol.2016.0259.

Authors

Reinhard Hohlfeld¹, Tania Kümpfel²

Affiliations

¹ Institute of Clinical Neuroimmunology, Biomedical Center and Klinikum Grosshadern, Munich, Germany2Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.
² Institute of Clinical Neuroimmunology, Biomedical Center and Klinikum Grosshadern, Munich, Germany.

PMID: 27042804
DOI: 10.1001/jamaneurol.2016.0259

No abstract available

Publication types

Editorial
Comment

MeSH terms

Alemtuzumab*
Humans
Interferon-beta
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting

Substances

Alemtuzumab
Interferon-beta